Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current perspectives on cardiovascular outcome trials in diabetes
Oliver Schnell, Lars Rydén, Eberhard Standl, et al.
Cardiovascular Diabetology (2016) Vol. 15, Iss. 1
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso, Darren K. McGuire, Bernard Zinman, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 8, pp. 723-732
Open Access | Times Cited: 537
Recent novel approaches to limit oxidative stress and inflammation in diabetic complications
R. J. Pickering, Carlos J. Rosado, Arpeeta Sharma, et al.
Clinical & Translational Immunology (2018) Vol. 7, Iss. 4
Open Access | Times Cited: 149
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Manfredi Rizzo, Dragana Nikolić, Angelo Maria Patti, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2018) Vol. 1864, Iss. 9, pp. 2814-2821
Closed Access | Times Cited: 129
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
Maria Isabel del Olmo-García, Juan Francisco Merino-Torres
Journal of Diabetes Research (2018) Vol. 2018, pp. 1-12
Open Access | Times Cited: 122
A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data
Evgenia Gourgari, Erin E. Wilhelm, Hamid Hassanzadeh, et al.
Journal of Diabetes and its Complications (2017) Vol. 31, Iss. 12, pp. 1719-1727
Open Access | Times Cited: 77
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
Francesco Prattichizzo, Lucia La Sala, Lars Rydén, et al.
European Journal of Preventive Cardiology (2019) Vol. 26, Iss. 2_suppl, pp. 73-80
Open Access | Times Cited: 66
Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
Oliver Schnell, Eberhard Standl, Doina Catrinoiu, et al.
Cardiovascular Diabetology (2016) Vol. 15, Iss. 1
Open Access | Times Cited: 58
Updates on cardiovascular outcome trials in diabetes
Oliver Schnell, Lars Rydén, Eberhard Standl, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 52
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
Alaaeldin Bashier, Azza Bin Hussain, Elamin Abdelgadir, et al.
Diabetology & Metabolic Syndrome (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 52
SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
Ashu Rastogi, Anil Bhansali
Diabetes Therapy (2017) Vol. 8, Iss. 6, pp. 1245-1251
Open Access | Times Cited: 50
The future of new drugs for diabetes management
Clifford J. Bailey, Caroline Day
Diabetes Research and Clinical Practice (2019) Vol. 155, pp. 107785-107785
Open Access | Times Cited: 44
Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
Oliver Schnell, Eberhard Standl, Doina Catrinoiu, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 38
Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function
Deepika Dasari, Srashti Goyal, Anuhya Penmetsa, et al.
European Journal of Pharmacology (2023) Vol. 949, pp. 175720-175720
Closed Access | Times Cited: 11
Antihyperglycaemic action of diosmin, a citrus flavonoid, is induced through endogenous β‐endorphin in type I‐like diabetic rats
Chia‐Chen Hsu, Mang Hung Lin, Juei‐Tang Cheng, et al.
Clinical and Experimental Pharmacology and Physiology (2017) Vol. 44, Iss. 5, pp. 549-555
Closed Access | Times Cited: 35
Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care
Jørgen Rungby, Morten Schou, Per Warrer, et al.
Cardiovascular Endocrinology (2017) Vol. 6, Iss. 4, pp. 145-151
Open Access | Times Cited: 33
Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs
Yue Fei, Man-Fung Tsoi, Cyrus R. Kumana, et al.
International Journal of Cardiology (2017) Vol. 254, pp. 291-296
Closed Access | Times Cited: 31
Visceral adipose tissue volume is associated with premature atherosclerosis in early type 2 diabetes mellitus independent of traditional risk factors
Melanie Reijrink, Stefanie A. de Boer, Daan Spoor, et al.
Atherosclerosis (2019) Vol. 290, pp. 87-93
Open Access | Times Cited: 28
NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Alena Welters, C. Alex Kluppel, Jessica Mrugala, et al.
Diabetes Obesity and Metabolism (2017) Vol. 19, Iss. S1, pp. 95-106
Open Access | Times Cited: 28
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Mafalda Ramos, V. Foos, Anastasia Ustyugova, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 6, pp. 2153-2167
Open Access | Times Cited: 24
Diosmin, a Citrus Nutrient, Activates Imidazoline Receptors to Alleviate Blood Glucose and Lipids in Type 1-Like Diabetic Rats
Chia-Chen Hsu, Mang Lin, Juei‐Tang Cheng, et al.
Nutrients (2017) Vol. 9, Iss. 7, pp. 684-684
Open Access | Times Cited: 24
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Lars Holger Ehlers, Mark Lamotte, Sofia Monteiro, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 5, pp. 1523-1534
Open Access | Times Cited: 16
Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes Research and Clinical Practice (2017) Vol. 127, pp. 224-237
Closed Access | Times Cited: 18
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
Lars Holger Ehlers, Mark Lamotte, Mafalda Ramos, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 3, pp. 489-503
Open Access | Times Cited: 9
Diabetes mellitus y riesgo cardiovascular. Actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Riesgo Cardiovascular de la Sociedad Española de Diabetes (SED, 2018)
Francisco Arrieta, Pedro Iglesias, Juan Pedro‐Botet, et al.
Clínica e Investigación en Arteriosclerosis (2018) Vol. 30, Iss. 3, pp. 137-153
Closed Access | Times Cited: 16
Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients
Kohei Kaku
Expert Opinion on Drug Safety (2017) Vol. 16, Iss. 11, pp. 1313-1322
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top